http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 17 Jun 2026 17:28:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17/26661031.html si-local-file:///var/storage/secattach/20260617/26661031.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17/26661031.html Wed, 17 Jun 2026 17:28:00 -0400 ACRV O.50727910 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17/26661031.html si-local-file:///var/storage/secattach/20260617/26661031.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Acrivon+Therapeutics%2C+++++For%3A+Jun+17/26661031.html Wed, 17 Jun 2026 17:28:00 -0400 ACRV O.50727910 http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).</p><p>The analyst commented, "We view the acquisition as a positive signal for small molecules and targeted oncology. Names we cover in the space include NUVB, EXEL (MO, $50 PT), RLAY (MO, $21 PT), FHTX (MO, $9 PT), ACRV (MO, $13 PT). We do not view NUVB's zidesamtinib as meaningfully differentiated from NUVB's Ibtrozi, which has a 1-year head start in 2L and more in 1L ROS1+ NSCLC, and remain bullish on the Ibtrozi launch trajectory as 1L patient stacking becomes more meaningful. http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html Wed, 10 Jun 2026 05:19:37 -0400 ACRV FHTX GSK NUVB RLAY http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).</p><p>The analyst commented, "We view the acquisition as a positive signal for small molecules and targeted oncology. Names we cover in the space include NUVB, EXEL (MO, $50 PT), RLAY (MO, $21 PT), FHTX (MO, $9 PT), ACRV (MO, $13 PT). We do not view NUVB's zidesamtinib as meaningfully differentiated from NUVB's Ibtrozi, which has a 1-year head start in 2L and more in 1L ROS1+ NSCLC, and remain bullish on the Ibtrozi launch trajectory as 1L patient stacking becomes more meaningful. http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html Wed, 10 Jun 2026 05:19:37 -0400 ACRV FHTX GSK NUVB RLAY http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).</p><p>The analyst commented, "We view the acquisition as a positive signal for small molecules and targeted oncology. Names we cover in the space include NUVB, EXEL (MO, $50 PT), RLAY (MO, $21 PT), FHTX (MO, $9 PT), ACRV (MO, $13 PT). We do not view NUVB's zidesamtinib as meaningfully differentiated from NUVB's Ibtrozi, which has a 1-year head start in 2L and more in 1L ROS1+ NSCLC, and remain bullish on the Ibtrozi launch trajectory as 1L patient stacking becomes more meaningful. http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html Wed, 10 Jun 2026 05:19:37 -0400 ACRV FHTX GSK NUVB RLAY http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).</p><p>The analyst commented, "We view the acquisition as a positive signal for small molecules and targeted oncology. Names we cover in the space include NUVB, EXEL (MO, $50 PT), RLAY (MO, $21 PT), FHTX (MO, $9 PT), ACRV (MO, $13 PT). We do not view NUVB's zidesamtinib as meaningfully differentiated from NUVB's Ibtrozi, which has a 1-year head start in 2L and more in 1L ROS1+ NSCLC, and remain bullish on the Ibtrozi launch trajectory as 1L patient stacking becomes more meaningful. http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html Wed, 10 Jun 2026 05:19:37 -0400 ACRV FHTX GSK NUVB RLAY http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html <p>Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $10.00 price target on Nuvation Bio Inc (NYSE: NUVB).</p><p>The analyst commented, "We view the acquisition as a positive signal for small molecules and targeted oncology. Names we cover in the space include NUVB, EXEL (MO, $50 PT), RLAY (MO, $21 PT), FHTX (MO, $9 PT), ACRV (MO, $13 PT). We do not view NUVB's zidesamtinib as meaningfully differentiated from NUVB's Ibtrozi, which has a 1-year head start in 2L and more in 1L ROS1+ NSCLC, and remain bullish on the Ibtrozi launch trajectory as 1L patient stacking becomes more meaningful. http://www.streetinsider.com/Analyst+Comments/Nuvation+Bio+%28NUVB%29+Reiterated+at+Market+Outperform+by+Citizens+Amid+Acquisition+by+GSK/26625792.html Wed, 10 Jun 2026 05:19:37 -0400 ACRV FHTX GSK NUVB RLAY http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+21++Filed+by%3A+Blume-Jensen+Peter/26550009.html si-local-file:///var/storage/secattach/20260526/26550009.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+21++Filed+by%3A+Blume-Jensen+Peter/26550009.html Tue, 26 May 2026 16:09:00 -0400 ACRV O.50727910 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+21++Filed+by%3A+Blume-Jensen+Peter/26550009.html si-local-file:///var/storage/secattach/20260526/26550009.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+21++Filed+by%3A+Blume-Jensen+Peter/26550009.html Tue, 26 May 2026 16:09:00 -0400 ACRV O.50727910 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Acrivon+Therapeutics%2C++++++++++++++++/26541515.html si-local-file:///var/storage/secattach/20260522/26541515.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Acrivon+Therapeutics%2C++++++++++++++++/26541515.html Fri, 22 May 2026 16:06:00 -0400 ACRV O.50727910 http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Acrivon+Therapeutics%2C++++++++++++++++/26541515.html si-local-file:///var/storage/secattach/20260522/26541515.html http://www.streetinsider.com/SEC+Filings/Form++DEFA14A++++Acrivon+Therapeutics%2C++++++++++++++++/26541515.html Fri, 22 May 2026 16:06:00 -0400 ACRV O.50727910 http://www.streetinsider.com/Press+Releases/Acrivon+Therapeutics+to+Present+at+TD+Cowen%E2%80%99s+7th+Annual+Oncology+Innovation+Summit/26531458.html <p align="justify">WATERTOWN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a virtual fireside chat on Tuesday, May 26, 2026, at 9:00 a.m. ET at TD Cowen’s 7^th Annual Oncology Innovation Summit.</p> <p>The live and archived webcast of this event can be accessed through http://www.streetinsider.com/Press+Releases/Acrivon+Therapeutics+to+Present+at+TD+Cowen%E2%80%99s+7th+Annual+Oncology+Innovation+Summit/26531458.html Thu, 21 May 2026 07:30:00 -0400 ACRV http://www.streetinsider.com/Globe+Newswire/Acrivon+Therapeutics+to+Present+at+TD+Cowen%E2%80%99s+7th+Annual+Oncology+Innovation+Summit/26531458.html <p align="justify">WATERTOWN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a virtual fireside chat on Tuesday, May 26, 2026, at 9:00 a.m. ET at TD Cowen’s 7^th Annual Oncology Innovation Summit.</p> <p>The live and archived webcast of this event can be accessed through http://www.streetinsider.com/Globe+Newswire/Acrivon+Therapeutics+to+Present+at+TD+Cowen%E2%80%99s+7th+Annual+Oncology+Innovation+Summit/26531458.html Thu, 21 May 2026 07:30:00 -0400 ACRV http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+Shah+Rajeev+M./26529318.html si-local-file:///var/storage/secattach/20260520/26529318.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+Shah+Rajeev+M./26529318.html Wed, 20 May 2026 17:00:00 -0400 ACRV O.50727910 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+Shah+Rajeev+M./26529318.html si-local-file:///var/storage/secattach/20260520/26529318.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+Shah+Rajeev+M./26529318.html Wed, 20 May 2026 17:00:00 -0400 ACRV O.50727910 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+TOMSICEK+MICHAEL+JOHN/26529011.html si-local-file:///var/storage/secattach/20260520/26529011.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+TOMSICEK+MICHAEL+JOHN/26529011.html Wed, 20 May 2026 16:37:00 -0400 ACRV O.50727910 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+TOMSICEK+MICHAEL+JOHN/26529011.html si-local-file:///var/storage/secattach/20260520/26529011.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+TOMSICEK+MICHAEL+JOHN/26529011.html Wed, 20 May 2026 16:37:00 -0400 ACRV O.50727910 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+Palani+Santhosh/26528997.html si-local-file:///var/storage/secattach/20260520/26528997.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+Palani+Santhosh/26528997.html Wed, 20 May 2026 16:36:00 -0400 ACRV O.50727910 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+Palani+Santhosh/26528997.html si-local-file:///var/storage/secattach/20260520/26528997.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+Palani+Santhosh/26528997.html Wed, 20 May 2026 16:36:00 -0400 ACRV O.50727910 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+Shacham+Sharon/26529005.html si-local-file:///var/storage/secattach/20260520/26529005.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+Shacham+Sharon/26529005.html Wed, 20 May 2026 16:36:00 -0400 ACRV O.50727910 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+Shacham+Sharon/26529005.html si-local-file:///var/storage/secattach/20260520/26529005.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+Shacham+Sharon/26529005.html Wed, 20 May 2026 16:36:00 -0400 ACRV O.50727910 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+Magovcevic-Liebisch+Ivana/26528993.html si-local-file:///var/storage/secattach/20260520/26528993.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+Magovcevic-Liebisch+Ivana/26528993.html Wed, 20 May 2026 16:35:00 -0400 ACRV O.50727910 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+Magovcevic-Liebisch+Ivana/26528993.html si-local-file:///var/storage/secattach/20260520/26528993.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+Magovcevic-Liebisch+Ivana/26528993.html Wed, 20 May 2026 16:35:00 -0400 ACRV O.50727910 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+DiRocco+Derek/26528968.html si-local-file:///var/storage/secattach/20260520/26528968.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+DiRocco+Derek/26528968.html Wed, 20 May 2026 16:34:00 -0400 ACRV O.50727910 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+DiRocco+Derek/26528968.html si-local-file:///var/storage/secattach/20260520/26528968.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Acrivon+Therapeutics%2C+++++For%3A+May+18++Filed+by%3A+DiRocco+Derek/26528968.html Wed, 20 May 2026 16:34:00 -0400 ACRV O.50727910